[go: up one dir, main page]

WO2000019997A8 - Controlled release dosage from comprising oxybutynin - Google Patents

Controlled release dosage from comprising oxybutynin

Info

Publication number
WO2000019997A8
WO2000019997A8 PCT/IB1998/001982 IB9801982W WO0019997A8 WO 2000019997 A8 WO2000019997 A8 WO 2000019997A8 IB 9801982 W IB9801982 W IB 9801982W WO 0019997 A8 WO0019997 A8 WO 0019997A8
Authority
WO
WIPO (PCT)
Prior art keywords
oxybutynin
controlled release
salt
release dosage
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001982
Other languages
French (fr)
Other versions
WO2000019997A1 (en
Inventor
David J Kidney
George V Guittard
Francisco Jao
Susan M Marks
Fernando Gumucio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to AU12563/99A priority Critical patent/AU1256399A/en
Priority to PCT/IB1998/001982 priority patent/WO2000019997A1/en
Publication of WO2000019997A1 publication Critical patent/WO2000019997A1/en
Publication of WO2000019997A8 publication Critical patent/WO2000019997A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a desethyl metabolite of oxybutynin and its reduction in the circulating plasma. Specifically the invention relates to a controlled release dosage form comprising oxybutynin or a pharmaceutically acceptable biologically active salt thereof adapted to release oxybutynin or its salt at a biological rate over time to an environment of use wherein the oxybutynin or active salt thereof is adapted to be partially converted to its desethylmetabolite in the environment of use and in that the rate of release of oxybutynin or salt thereof from the dosage form is adapted to provide a controlled release of up to 30 hours to provide a higher oxybutynin/desethyl metabolite ratio than 0.18:1 or such that the plasma levels of the metabolite do not exceed 350 ng.h/ml in use.
PCT/IB1998/001982 1998-10-07 1998-10-07 Controlled release dosage from comprising oxybutynin Ceased WO2000019997A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU12563/99A AU1256399A (en) 1998-10-07 1998-10-07 Controlled release dosage from comprising oxybutynin
PCT/IB1998/001982 WO2000019997A1 (en) 1998-10-07 1998-10-07 Controlled release dosage from comprising oxybutynin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1998/001982 WO2000019997A1 (en) 1998-10-07 1998-10-07 Controlled release dosage from comprising oxybutynin

Publications (2)

Publication Number Publication Date
WO2000019997A1 WO2000019997A1 (en) 2000-04-13
WO2000019997A8 true WO2000019997A8 (en) 2000-07-27

Family

ID=11004787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001982 Ceased WO2000019997A1 (en) 1998-10-07 1998-10-07 Controlled release dosage from comprising oxybutynin

Country Status (2)

Country Link
AU (1) AU1256399A (en)
WO (1) WO2000019997A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436428B1 (en) 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2665858B2 (en) * 1992-05-30 1997-10-22 日本ヘキスト・マリオン・ルセル株式会社 Long-acting oxybutynin hydrochloride preparation
JP2646170B2 (en) * 1992-06-24 1997-08-25 日本ヘキスト・マリオン・ルセル株式会社 Sustained-release oxybutynin hydrochloride preparation
WO1996012477A1 (en) * 1994-10-21 1996-05-02 Leiras Oy Controlled release oral delivery system containing oxybutynin
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals

Also Published As

Publication number Publication date
WO2000019997A1 (en) 2000-04-13
AU1256399A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
AU8142594A (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
AU1089997A (en) Hyperabas: biologically active abscisic acid analogs with unsaturated carbon substituents at the 8'-methyl or 9'-methyl carbon atoms
CA2251331A1 (en) Calcilytic compounds
EP2266607A3 (en) Immunoconjugates for treating cancer
EP2322187A3 (en) Use of uridine in combination with choline for the treatment of memory disorders
AU2466099A (en) Pharmaceutically active compounds and methods of use thereof
CA2016659A1 (en) Stabilized compositions containing epidermal growth factor
ITMI922953A1 (en) DOUBLE BIOLOGICAL ACTIVITY OF NO SYNTHASIS AND CYCLOOXYGENES PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN THEM.
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
IL129335A0 (en) Local anesthetic for external use
IL111252A0 (en) Dihalopropene compound, insecticide/acaricide containing said dihalopropene compound as active ingredient,and intermediate compound for use in production of said dihalopropene compound
WO2002002056A3 (en) Method of treatment of seborrheic dermatitis
MY113718A (en) Pharmaceutical formulation containing a hydrophobic active substance and an effervescent system, and process for the preparation of the formulation
IL133442A0 (en) Controlled release pharmaceutical preparation with ace inhibitor as active agent
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
UA74388C2 (en) Pharmaceutical compositions of tysoxanide and nitasoxanide
ZA941199B (en) Physiologically active compound HS-1 and process for the preparation of the same
WO2000019997A8 (en) Controlled release dosage from comprising oxybutynin
WO2001081328A3 (en) Thiazolidinedione analogues and their use for the treatment of diabetes
AU1755092A (en) Preparation of 3'-substituted-2',3'-dideoxynucleosides and 2'-deoxynucleosides from acyclic, achiral precursors
IL148907A0 (en) Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
CA2248837A1 (en) Method and composition for enhancing biocidal activity
IL127851A0 (en) Inhibition of TNF activity
NZ334949A (en) Stabilised pharmaceutical composition of quinupristine and dalfopristine with methanesulphonic acid or hydrochloric acid
WO2002007715A3 (en) A method for treating celiac disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase